N-Acetyl-L-Leucine not checked
IntraBio Inc · IB1001
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)”In the company’s words, NCT06673056 on ClinicalTrials.gov
- Tested for
- Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T), CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2, Familial Hemiplegic Migraine-1, Niemann-Pick Disease, Type C
- Main trialPhase 3
- “A pivotal, randomized, double-blind, placebo-controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of Ataxia-Telangiectasia (A-T). The objective of this study is to evaluate the safety, tolerability and efficacy of N-acetyl-L-leucine (IB1001) compared to standard of care.”In the company’s words, NCT06673056 on ClinicalTrials.gov
- Other names
- IB1001 · levacetylleucine
Other drugs for Spinocerebellar Ataxia Type 6
- Human umbilical cord mesenchymal stem cellSclnow Biotechnology Co., Ltd. · Phase 2
- VO659Vico Therapeutics B. V. · Phase 1/2
Coming up3
- 31 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 1 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 12 Jun 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Dec 2027 | A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T) | |
| Phase 3Active, not recruiting | 1 May 2028 | Pivotal Study of N-acetyl-L-leucine for CACNA1A | |
| Phase 3Recruiting | 12 Jun 2030 | A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026